Have a feature idea you'd love to see implemented?
Let us know!
HROW Harrow Health Inc
Price (delayed)
$43.88
Market cap
$1.56B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$1.69B
Harrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton
Highlights
HROW's gross profit has soared by 54% YoY and by 12% QoQ
HROW's revenue is up by 48% year-on-year and by 10% since the previous quarter
Harrow Health's net income has plunged by 135% YoY
The EPS has dropped by 111% year-on-year
Key stats
What are the main financial stats of HROW
Market
Valuations
Earnings
Shares outstanding
35.61M
Market cap
$1.56B
Enterprise value
$1.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
26.86
Price to sales (P/S)
9.26
EV/EBIT
N/A
EV/EBITDA
1,583.32
EV/Sales
9.97
Revenue
$169.14M
EBIT
-$11.73M
EBITDA
$1.07M
Free cash flow
$3.04M
Per share
Balance sheet
Liquidity
EPS
-$0.95
Free cash flow per share
$0.09
Book value per share
$1.63
Revenue per share
$4.74
TBVPS
$4.48
Total assets
$351.54M
Total liabilities
$293.92M
Debt
$196.06M
Equity
$57.98M
Working capital
$52.06M
Debt to equity
3.38
Current ratio
1.55
Quick ratio
1.33
Net debt/EBITDA
115.93
Margins
Efficiency
Dividend
EBITDA margin
0.6%
Gross margin
72.6%
Net margin
-19.8%
Operating margin
-5.3%
Return on assets
-10.6%
Return on equity
-53.9%
Return on invested capital
-5.6%
Return on capital employed
-4.6%
Return on sales
-6.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HROW stock price
How has the Harrow Health stock price performed over time
Intraday
3.39%
1 week
2.38%
1 month
-22.23%
1 year
375.92%
YTD
291.79%
QTD
-2.4%
Financial performance
How have Harrow Health's revenue and profit performed over time
Revenue
$169.14M
Gross profit
$122.73M
Operating income
-$8.95M
Net income
-$33.41M
Gross margin
72.6%
Net margin
-19.8%
Harrow Health's net income has plunged by 135% YoY
Harrow Health's net margin has plunged by 60% YoY but it has increased by 9% from the previous quarter
HROW's gross profit has soared by 54% YoY and by 12% QoQ
HROW's revenue is up by 48% year-on-year and by 10% since the previous quarter
Growth
What is Harrow Health's growth rate over time
Valuation
What is Harrow Health stock price valuation
P/E
N/A
P/B
26.86
P/S
9.26
EV/EBIT
N/A
EV/EBITDA
1,583.32
EV/Sales
9.97
The EPS has dropped by 111% year-on-year
The stock's price to book (P/B) is 100% more than its last 4 quarters average of 13.4
Harrow Health's equity has decreased by 23% YoY
HROW's P/S is 132% above its 5-year quarterly average of 4.0 and 82% above its last 4 quarters average of 5.1
HROW's revenue is up by 48% year-on-year and by 10% since the previous quarter
Efficiency
How efficient is Harrow Health business performance
The return on assets has dropped by 66% year-on-year but it is up by 5% since the previous quarter
Harrow Health's return on equity has decreased by 40% YoY and by 7% QoQ
The ROIC has contracted by 22% from the previous quarter
The return on sales has declined by 4.5% since the previous quarter
Dividends
What is HROW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HROW.
Financial health
How did Harrow Health financials performed over time
The total assets is 20% greater than the total liabilities
Harrow Health's current ratio has shrunk by 73% YoY and by 40% QoQ
Harrow Health's quick ratio has plunged by 73% YoY and by 42% from the previous quarter
The debt to equity has grown by 35% YoY and by 2.7% from the previous quarter
Harrow Health's equity has decreased by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.